RxDoctor Payments Data

Artin Mahmoudi, MD

Critical Care Medicine · Ukiah, CANPI 1265786552

Payments from drug & device makers

$3,632in general payments, 2019–2025

Across 184 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$826
  • Boehringer Ingelheim$666
  • Regeneron Healthcare Solutions, Inc.$300
  • Bayer$265
  • Amgen$176
  • plus $387 from 8 others

What the payments were for

  • Consulting fees$2006%
  • Food & beverage$3,42594%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,632 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$160,145
Medicare patients
717
Services billed
2,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate33$422,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter431$412,993
Dupixent PenDupilumab43$192,205
Breztri AerosphereBudesonide/Glycopyr/Formoterol175$161,011
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr188$114,560
Breo ElliptaFluticasone/Vilanterol148$91,552
Fasenra PenBenralizumab15$83,848
Stiolto RespimatTiotropium Br/Olodaterol Hcl91$68,372
Dupixent SyringeDupilumab13$49,857
EliquisApixaban42$29,194
Spiriva RespimatTiotropium Bromide22$24,102
XareltoRivaroxaban13$18,144
SymbicortBudesonide/Formoterol Fumarate42$17,990
Albuterol Sulfate HfaAlbuterol Sulfate446$16,359
Roflumilast74$11,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$826$619,104767 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$666$514,509146 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,012$179,000217 claims
Johnson & JohnsonXarelto$24$18,14413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Ukiah

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →